First Manhattan CO Obs Eva Sa Transaction History

First Manhattan CO

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$2.01 - $5.05 $3,014 - $7,575	-1,500 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$1.89 - $2.55 $2,835 - $3,824	1,500 New	1,500 $3,000
Q3 2020 Nov 12, 2020	SELL	$2.46 - $6.15 $738 - $1,845	-300 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$2.01 - $5.95 $2,914 - $8,627	-1,450 Reduced 82.86%	300 $1,000
Q1 2020 May 06, 2020	BUY	$1.87 - $4.47 $3,272 - $7,822	1,750 New	1,750 $4,000
Q4 2019 Feb 13, 2020	SELL	$2.48 - $8.1 $4.29 Million - $14 Million	-1,729,143 Closed	0 $0
Q3 2019 Nov 13, 2019	SELL	$8.22 - $11.2 $2.77 Million - $3.78 Million	-337,169 Reduced 16.32%	1,729,143 $14.4 Million
Q2 2019 Aug 16, 2019	SELL	$10.05 - $14.25 $58,290 - $82,650	-5,800 Reduced 0.28%	2,066,312 $23.4 Million
Q1 2019 Apr 12, 2019	SELL	$11.82 - $14.48 $531,900 - $651,600	-45,000 Reduced 2.13%	2,072,112 $26.5 Million
Q4 2018 Jan 30, 2019	BUY	$10.8 - $17.94 $6.31 Million - $10.5 Million	584,646 Added 38.15%	2,117,112 $26.8 Million
Q3 2018 Oct 15, 2018	BUY	$10.92 - $18.18 $256,620 - $427,230	23,500 Added 1.56%	1,532,466 $27.6 Million
Q2 2018 Aug 01, 2018	BUY	$10.0 - $17.87 $5.09 Million - $9.1 Million	508,966 Added 50.9%	1,508,966 $22.8 Million
Q4 2017 Jan 22, 2018	BUY	$8.48 - $12.0 $8.48 Million - $12 Million	1,000,000	1,000,000 $9.76 Million

88K

Ticker OBSV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,499,200
Description
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometrio...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.